A Phase III, Randomized, Open-Label Study Evaluating Efficacy And Safety Of Giredestrant Compared With Fulvestrant, Both Combined With A CDK4/6 Inhibitor, In Patients With Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer With Resistance To Prior Adjuvant Endocrine Therapy